{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:58Z","timestamp":1790795218890,"version":"4.1.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1001\/jamacardio.2016.4828","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T12:34:30Z","timestamp":1482928470000},"page":"370","source":"Crossref","is-referenced-by-count":169,"title":["Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes"],"prefix":"10.1001","volume":"2","author":[{"given":"Marshall B.","family":"Elam","sequence":"first","affiliation":[{"name":"Memphis Veterans Affairs Medical Center and University of Tennessee Health Sciences Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Lovato","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Wake Forest, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Corson","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Largay","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lopez","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Atlanta Veterans Affairs Medical Center, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weiss","sequence":"additional","affiliation":[{"name":"Diabetes Endocrine Nutrition Group, Mentor, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Friedewald","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hertzel C.","family":"Gerstein","sequence":"additional","affiliation":[{"name":"McMaster Medical Center, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Probstfield","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grimm","sequence":"additional","affiliation":[{"name":"Berman Center for Outcomes and Clinical Research, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[{"name":"Cleveland Veterans Affairs Medical Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"David C.","family":"Goff","sequence":"additional","affiliation":[{"name":"Colorado School of Public Health, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome L.","family":"Fleg","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, Division of Cardiovascular Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, Division of Cardiovascular Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Byington","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Wake Forest, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ACCORDION Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"hoi160088r1","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1001\/archinte.164.13.1422","article-title":"The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.","volume":"164","author":"Almdal","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"hoi160088r2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"issue":"4","key":"hoi160088r3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi160088r4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/diacare.21.1.69","article-title":"Impact of diabetes on mortality after the first myocardial infarction.","volume":"21","author":"Miettinen","year":"1998","journal-title":"Diabetes Care"},{"issue":"3","key":"hoi160088r5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ecl.2006.06.002","article-title":"Diabetic dyslipidemia.","volume":"35","author":"Chahil","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7134","key":"hoi160088r6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"issue":"12A","key":"hoi160088r7","doi-asserted-by":"publisher","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"issue":"20","key":"hoi160088r8","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"hoi160088r9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi160088r10","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes.","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"17","key":"hoi160088r11","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus.","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi160088r12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes.","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi160088r13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2337\/dc15-2283","article-title":"Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes.","volume":"39","author":"ACCORD Study Group","year":"2016","journal-title":"Diabetes Care"},{"issue":"12A","key":"hoi160088r14","doi-asserted-by":"publisher","first-page":"4i","DOI":"10.1016\/j.amjcard.2007.03.002","article-title":"Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.","volume":"99","author":"Goff","year":"2007","journal-title":"Am J Cardiol"},{"issue":"12A","key":"hoi160088r15","doi-asserted-by":"publisher","first-page":"56i","DOI":"10.1016\/j.amjcard.2007.03.024","article-title":"Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.","volume":"99","author":"Ginsberg","year":"2007","journal-title":"Am J Cardiol"},{"issue":"15","key":"hoi160088r16","first-page":"1905","article-title":"ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.","volume":"18","author":"Harmonised Tripartite Guideline","year":"1999","journal-title":"Stat Med"},{"issue":"2","key":"hoi160088r17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"hoi160088r18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes.","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi160088r19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/diacare.29.03.06.dc05-1254","article-title":"Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey.","volume":"29","author":"Resnick","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"hoi160088r20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"6","key":"hoi160088r21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"20","key":"hoi160088r22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi160088r23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.","volume":"102","author":"Bezafibrate Infarction Prevention (BIP) study","year":"2000","journal-title":"Circulation"},{"issue":"9500","key":"hoi160088r24","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"22","key":"hoi160088r25","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome.","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"issue":"24","key":"hoi160088r26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi160088r27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients.","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"hoi160088r28","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"hoi160088r29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"hoi160088r30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi160088r31","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi160088r32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes.","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi160088r33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"hoi160088r34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jama.1988.03410050061031","article-title":"Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.","volume":"260","author":"Manninen","year":"1988","journal-title":"JAMA"},{"issue":"12","key":"hoi160088r35","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"hoi160088r36","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1007\/s00125-014-3344-3","article-title":"Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.","volume":"57","author":"d\u2019Emden","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"hoi160088r37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"issue":"11","key":"hoi160088r38","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes.","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"hoi160088r39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"hoi160088r40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/dc13-0790","article-title":"Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.","volume":"37","author":"Linz","year":"2014","journal-title":"Diabetes Care"},{"issue":"24","key":"hoi160088r41","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes.","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2594262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T18:01:09Z","timestamp":1549994469000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2016.4828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2016.4828","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,1]]}}}